Screener
Ultragenyx Pharmaceutical RARE Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $125M-29.0% | $175M+37.8% | $421M+142% | $202.51M+34.5% | $176M-63.4% | ||
| $167M-46.4% | $238M-35.2% | $259M-40.6% | $222.74M-52.7% | $311.28M+9.9% | ||
| $200M+60.7% | $121M+22.4% | $158M+29.5% | $112.54M+20.6% | $124.46M+17.4% | ||
| $59M+26.9% | $55M+19.5% | $52M+15.6% | $52.2M+20.5% | $46.5M+15.8% | ||
| $606M-15.8% | $657M-6.0% | $951M+16.4% | $643.21M-19.6% | $719.79M-25.4% | ||
| $235M-8.1% | $239M-8.4% | $244M-8.3% | $249.96M-8.3% | $255.76M-8.2% | ||
| $44M-0.9% | $44M-0.9% | $44M0.0% | $44.41M0.0% | $44.41M0.0% | ||
| $172M-1.6% | $174M-1.4% | $176M-1.1% | $172.94M+4.9% | $174.73M+5.1% | ||
| $1.26B-3.2% | $1.3B-1.2% | $1.53B+1.9% | $1.19B-22.6% | $1.31B-19.3% | ||
| $351M+19.7% | $325M+11.4% | $384M+11.6% | $340.02M+19.3% | $293.24M+7.5% | ||
| $1.55B+34.8% | $1.53B+31.4% | $1.61B+29.3% | $1.17B-0.9% | $1.15B-3.2% | ||
| $0-100% | $0-100% | $0— | $96K+4.3% | $96K+4.3% | ||
| -$4.81B-13.9% | -$4.72B-14.8% | -$4.53B-14.5% | -$4.4B-15.2% | -$4.22B-14.4% | ||
| -$291M-293% | -$236M-264% | -$80M-131% | $9.16M-97.4% | $151M-65.1% | ||
| $1.26B-3.2% | $1.3B-1.2% | $1.53B+1.9% | $1.19B-22.6% | $1.31B-19.3% |
FAQ
- What are Ultragenyx Pharmaceutical's total assets?
- Ultragenyx Pharmaceutical (RARE) holds $1.3B in total assets, down 3.2% year over year.
- How much cash does Ultragenyx Pharmaceutical have?
- Ultragenyx Pharmaceutical holds $125.0M in cash and equivalents.
- Can Ultragenyx Pharmaceutical cover its short-term obligations?
- Its current ratio is 1.73 — current assets exceed current liabilities.
- Where does Ultragenyx Pharmaceutical's balance sheet data come from?
- Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
